Clinical characteristics and outcomes in those with primary extrahepatic malignancy and malignant ascites

Background Malignancy-related ascites accounts for approximately 10% of causes of ascites. Our AIM was to characterize the ascites fluid and correlate clinical outcomes in those with extrahepatic malignancy and ascites. Methods 241 subjects with extrahepatic solid tumors and ascites were reviewed fr...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:BMC gastroenterology Ročník 22; číslo 1; s. 410 - 9
Hlavní autori: Alshuwaykh, Omar, Cheung, Amanda, Goel, Aparna, Kwong, Allison, Dhanasekaran, Renumathy, Ghaziani, T. Tara, Ahmed, Aijaz, Daugherty, Tami, Dronamraju, Deepti, Kumari, Radhika, Nguyen, Mindie, Kim, W. Ray, Kwo, Paul Yien
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London BioMed Central 05.09.2022
BioMed Central Ltd
Springer Nature B.V
BMC
Predmet:
Ascites
Ascites - etiology
Ascitic Fluid - chemistry
Cancer
Cancer therapies
Care and treatment
Cellular biology
Chemotherapy
Colorectal cancer
Cytology
Diagnosis
Diuretics
Etiology
Gastric cancer
Gastroenterology
Health aspects
Hepatology
Humans
Hypertension, Portal - complications
Immunotherapy
Internal Medicine
Kidney cancer
Liver
Liver cancer
Liver diseases
Liver Neoplasms - secondary
Lung cancer
Malignancy
Malignant ascites
Measurement
Medicine
Medicine & Public Health
Metastases
Metastasis
Mortality
Ovarian cancer
Pancreatic cancer
Pancreatic Neoplasms
Pancreatic Neoplasms - complications
Patient outcomes
Peritoneal carcinomatosis
Peritoneal Neoplasms - secondary
Peritoneum
Portal hypertension
Prevention
Proteins
Pulmonary hypertension
Research Article
Risk factors
Serum ascites albumin gradient
Solid tumors
Survival analysis
Tuberculosis
Tumors
United States
Malignant ascites
Peritoneal carcinomatosis
Portal hypertension
Serum ascites albumin gradient
ISSN:1471-230X, 1471-230X
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Background Malignancy-related ascites accounts for approximately 10% of causes of ascites. Our AIM was to characterize the ascites fluid and correlate clinical outcomes in those with extrahepatic malignancy and ascites. Methods 241 subjects with extrahepatic solid tumors and ascites were reviewed from 1/1/2000 to 12/31/2019, 119 without liver metastasis and 122 with liver metastasis. Results Ascites fluid consistent with peritoneal carcinomatosis (PC) was most common, 150/241 (62%), followed by fluid reflecting the presence of portal hypertension (PH), 69/241 (29%). 22/241 (9%) had low SAAG and low ascites fluid total protein, with evidence of PC on cytology and or imaging in 20/22. Lung cancer was the most common malignancy in subjects with ascites due to PC at 36/150 (24%), pancreatic cancer was the most common in subjects with ascites with features of PH at 16/69 (23%). Chemotherapy or immunotherapy alone was the most common management approach. Significantly higher 5-year, 3-year and 1-year mortality rate were noted in subjects with evidence of PC on cytology/imaging versus subjects with no evidence of PC, and in subjects with liver metastasis compared to subjects without liver metastasis. Subjects with pancreatic cancer and evidence of PC on cytology/imaging had higher 1 and 5-year mortality rates compared to subjects without PC. Conclusions Ascites in solid tumor malignancy is most commonly due to PC. We also observed ascites fluid with characteristics of PH in 29% of subjects. Higher mortality rates in subjects with peritoneal carcinomatosis and liver metastasis were noted. These findings may help inform prognosis and treatment strategies.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1471-230X
1471-230X
DOI:10.1186/s12876-022-02487-4